1. Home
  2. TARS vs TMDX Comparison

TARS vs TMDX Comparison

Compare TARS & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tarsus Pharmaceuticals Inc.

TARS

Tarsus Pharmaceuticals Inc.

HOLD

Current Price

$69.20

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Logo TransMedics Group Inc.

TMDX

TransMedics Group Inc.

HOLD

Current Price

$88.58

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TARS
TMDX
Founded
2016
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.6B
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
TARS
TMDX
Price
$69.20
$88.58
Analyst Decision
Buy
Buy
Analyst Count
6
9
Target Price
$89.00
$148.22
AVG Volume (30 Days)
831.4K
969.9K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
48.21
382.18
EPS
N/A
0.61
Revenue
$451,360,000.00
$605,494,000.00
Revenue This Year
$56.43
$24.25
Revenue Next Year
$30.19
$18.75
P/E Ratio
N/A
$146.95
Revenue Growth
146.71
37.13
52 Week Low
$48.20
$60.11
52 Week High
$85.25
$156.00

Technical Indicators

Market Signals
Indicator
TARS
TMDX
Relative Strength Index (RSI) 65.51 64.49
Support Level $60.95 $66.64
Resistance Level $73.45 $152.95
Average True Range (ATR) 3.30 4.31
MACD 1.12 1.16
Stochastic Oscillator 84.67 92.03

Price Performance

Historical Comparison
TARS
TMDX

About TARS Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Share on Social Networks: